ProBioGen in deal with Millennium

8 November 2004

Berlin, Germany-based ProBioGen has entered into a cell line development program with Millennium Pharmaceuticals of the USA. Under the customized program, ProBioGen will use its Position Mediated Expression Enhancement strategy, which has proved successful in the development of high-yielding cell lines, to develop cell lines for the US company's antibodies and manufacture preclinical trial materials.

Through the use of Boost Elements and a specific design, ProBioGen claims it is in a position to shorten development time and meet customer expectations even under aggressive timelines.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight